Literature DB >> 20538607

Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation.

Indira Jutooru1, Gayathri Chadalapaka, Ping Lei, Stephen Safe.   

Abstract

Curcumin activates diverse anticancer activities that lead to inhibition of cancer cell and tumor growth, induction of apoptosis, and antiangiogenic responses. In this study, we observed that curcumin inhibits Panc28 and L3.6pL pancreatic cancer cell and tumor growth in nude mice bearing L3.6pL cells as xenografts. In addition, curcumin decreased expression of p50 and p65 proteins and NFkappaB-dependent transactivation and also decreased Sp1, Sp3, and Sp4 transcription factors that are overexpressed in pancreatic cancer cells. Because both Sp transcription factors and NFkappaB regulate several common genes such as cyclin D1, survivin, and vascular endothelial growth factor that contribute to the cancer phenotype, we also investigated interactions between Sp and NFkappaB transcription factors. Results of Sp1, Sp3, and Sp4 knockdown by RNA interference demonstrate that both p50 and p65 are Sp-regulated genes and that inhibition of constitutive or tumor necrosis factor-induced NFkappaB by curcumin is dependent on down-regulation of Sp1, Sp3, and Sp4 proteins by this compound. Curcumin also decreased mitochondrial membrane potential and induced reactive oxygen species in pancreatic cancer cells, and this pathway is required for down-regulation of Sp proteins in these cells, demonstrating that the mitochondriotoxic effects of curcumin are important for its anticancer activities.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538607      PMCID: PMC2919096          DOI: 10.1074/jbc.M109.095240

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

Review 1.  Pancreatic cancer: from genes to patient care.

Authors:  R H Hruban
Journal:  J Gastrointest Surg       Date:  2001 Nov-Dec       Impact factor: 3.452

Review 2.  Focus on pancreas cancer.

Authors:  Elizabeth M Jaffee; Ralph H Hruban; Marcia Canto; Scott E Kern
Journal:  Cancer Cell       Date:  2002-07       Impact factor: 31.743

Review 3.  Anticancer potential of curcumin: preclinical and clinical studies.

Authors:  Bharat B Aggarwal; Anushree Kumar; Alok C Bharti
Journal:  Anticancer Res       Date:  2003 Jan-Feb       Impact factor: 2.480

Review 4.  Molecular epidemiology of pancreatic cancer.

Authors:  D Li
Journal:  Cancer J       Date:  2001 Jul-Aug       Impact factor: 3.360

5.  Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.

Authors:  S R Bramhall; A Rosemurgy; P D Brown; C Bowry; J A Buckels
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

6.  Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma.

Authors:  Naomi Y Jiang; Bruce A Woda; Barbara F Banner; Giles F Whalen; Karen A Dresser; Di Lu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07       Impact factor: 4.254

7.  Phase II trial of curcumin in patients with advanced pancreatic cancer.

Authors:  Navneet Dhillon; Bharat B Aggarwal; Robert A Newman; Robert A Wolff; Ajaikumar B Kunnumakkara; James L Abbruzzese; Chaan S Ng; Vladimir Badmaev; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

8.  Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  M J Moore; J Hamm; J Dancey; P D Eisenberg; M Dagenais; A Fields; K Hagan; B Greenberg; B Colwell; B Zee; D Tu; J Ottaway; R Humphrey; L Seymour
Journal:  J Clin Oncol       Date:  2003-09-01       Impact factor: 44.544

Review 9.  The medical management of pancreatic cancer: a review.

Authors:  Sarah McKenna; Martin Eatock
Journal:  Oncologist       Date:  2003

Review 10.  Chemotherapy for advanced pancreatic cancer.

Authors:  Daniel G Haller
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003       Impact factor: 7.038

View more
  80 in total

1.  Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: role of Sp transcription factors and microRNA-27a:ZBTB10.

Authors:  Susanne U Mertens-Talcott; Giuliana D Noratto; Xiangrong Li; Gabriela Angel-Morales; Michele C Bertoldi; Stephen Safe
Journal:  Mol Carcinog       Date:  2012-03-07       Impact factor: 4.784

2.  Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling.

Authors:  Xiang-Lin Tan; Kalyan K Bhattacharyya; Shamit K Dutta; William R Bamlet; Kari G Rabe; Enfeng Wang; Thomas C Smyrk; Ann L Oberg; Gloria M Petersen; Debabrata Mukhopadhyay
Journal:  Pancreas       Date:  2015-05       Impact factor: 3.327

3.  The Chinese herb isolate yuanhuacine (YHL-14) induces G2/M arrest in human cancer cells by up-regulating p21 protein expression through an p53 protein-independent cascade.

Authors:  Ruowen Zhang; Yulei Wang; Jingxia Li; Honglei Jin; Shaojiang Song; Chuanshu Huang
Journal:  J Biol Chem       Date:  2014-01-22       Impact factor: 5.157

4.  Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1.

Authors:  Sulagna Banerjee; Veena Sangwan; Olivia McGinn; Rohit Chugh; Vikas Dudeja; Selwyn M Vickers; Ashok K Saluja
Journal:  J Biol Chem       Date:  2013-10-15       Impact factor: 5.157

5.  Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors.

Authors:  Erik Hedrick; Xi Li; Stephen Safe
Journal:  Mol Cancer Ther       Date:  2016-11-03       Impact factor: 6.261

6.  Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors.

Authors:  Gayathri Chadalapaka; Indira Jutooru; Sandeep Sreevalsan; Satya Pathi; Kyounghyun Kim; Candy Chen; Lisa Crose; Corinne Linardic; Stephen Safe
Journal:  Int J Cancer       Date:  2012-08-03       Impact factor: 7.396

Review 7.  The Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome.

Authors:  Yiwei Li; Vay Liang W Go; Fazlul H Sarkar
Journal:  Pancreas       Date:  2015-01       Impact factor: 3.327

8.  Active curcumin nanoparticles formed from a volatile microemulsion template.

Authors:  K Margulis; S Srinivasan; M J Ware; H D Summers; B Godin; S Magdassi
Journal:  J Mater Chem B       Date:  2014       Impact factor: 6.331

9.  Effects of cyclohexanone analogues of curcumin on growth, apoptosis and NF-κB activity in PC-3 human prostate cancer cells.

Authors:  Xingchuan Wei; Zhi-Yun DU; Xiao-Xing Cui; Michael Verano; Rong Qing Mo; Zhi Kai Tang; Allan H Conney; Xi Zheng; Kun Zhang
Journal:  Oncol Lett       Date:  2012-05-10       Impact factor: 2.967

Review 10.  Minireview: role of orphan nuclear receptors in cancer and potential as drug targets.

Authors:  Stephen Safe; Un-Ho Jin; Erik Hedrick; Alexandra Reeder; Syng-Ook Lee
Journal:  Mol Endocrinol       Date:  2013-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.